From antiangiogenesis to hypoxia: current research and future directions

Christopher Rice1
L Eric Huang1,2
1Department of Neurosurgery,
2Department of Oncological Sciences,
University of Utah, Salt Lake City,
UT, USA

Abstract: Antiangiogenesis has long been recognized as an essential element in tumor growth. Since the conception of antiangiogenesis for cancer therapeutics, great strides have been made in understanding the molecular biology underlying angiogenesis, both in cancer and in physiology. By capitalizing on these advancements through bench-to-bedside research, potent antiangiogenic agents have been developed and tested. To date, the clinical results of most of these antiangiogenic agents have not met expectations. Even with the most successful agents, such as bevacizumab, used either as single agents or in combination with chemotherapy, gains in overall survival of cancer patients have been modest in most cases. In this article, the authors present the evolving views of antiangiogenic therapy, review recent experimental and clinical studies on antiangiogenesis, and address the fundamental role of hypoxia in tumor progression, which may be key to improving the efficacy of antiangiogenic therapy.

Keywords: antiangiogenesis, genetic alteration, hypoxia, tumor progression

Angiogenesis, tumor growth, and antiangiogenesis

Recognition of the association between vigorous neovascularization (angiogenesis) and tumor growth dates back to the first half of the 20th century.1,2 However, the significance of this finding and the relationship between new vessel growth and tumor growth were not fully appreciated until many years later. Folkman and others first showed that, in the absence of vascularization, tumor growth arrested when the tumor reached 2–3 mm in diameter, presumably owing to limited diffusion of oxygen, nutrients, and waste products. Furthermore, small, dormant tumors would quickly resume expansion when allowed to initiate neovascularization.3-5

An angiogenic factor was later isolated from human and animal tumors that is mitogenic to endothelial cells and stimulates the rapid formation of new capillaries in animals.6 Folkman proposed targeting this angiogenic factor for angiogenic inhibition as a strategy for cancer therapy, which is the fundamental premise of antiangiogenesis therapy. This unconventional approach seemed promising for several reasons. First, fewer side effects were expected from inhibiting angiogenesis than from traditional cytotoxic agents, presumably because new vessel growth in an adult patient is less important under most physiologic conditions (eg, in the absence of wound healing). Second, it seemed plausible that, in addition to restricting tumor growth to the limits of direct diffusion of nutrients and waste metabolites, reduced access to the vasculature would decrease distant metastasis. Third, by targeting the vasculature, one would expect less likelihood of developing resistance from endothelial cells than from tumor cells.7,8
Identifying this angiogenic factor, however, proved to be challenging. In time, it became apparent that there were many different factors involved in stimulating angiogenesis. The first to be identified was the basic fibroblast growth factor (bFGF),9 which was shown to directly stimulate endothelial cell proliferation.10 A few years later, vascular endothelial growth factor (VEGF) was identified, cloned,11,12 and characterized as a potent regulator of angiogenesis via mitogenic and antiapoptotic signaling in endothelial cells.13,14 As an increasing number of angiogenic regulators were identified and characterized, including the angiopoietins,15,16 interleukin 8,17,18 and others, a more cohesive view of the mechanisms of angiogenesis in tumor growth developed.

Angiogenic switch

In 1991, Hanahan and colleagues further developed the theory that angiogenesis is required for continued tumor growth by demonstrating a switch from low to high vessel density during the multistep process of fibrosarcoma progression in transgenic mice.19 It was found that cells cultured from advanced preneoplastic lesions secreted bFGF into the growth medium, whereas cells derived from lower-grade lesions did not. This ‘angiogenic switch’ correlated not only with histologically higher-grade tumors but also with tumorigenicity. Similar results seen in islet cell carcinoma and epidermal squamous cell carcinoma mouse models added additional evidence to the idea that the switch to an angiogenic phenotype is a discrete step during tumor progression and essential for solid tumor growth.20

The importance of tumor angiogenesis became more apparent as the underlying mechanisms began to come into focus. Folkman’s vision of developing antiangiogenic cancer therapies also began to seem within reach as interest increased. This step forward, however, did not come without hindrance.

Setbacks for antiangiogenic therapy

Despite the promising preclinical and animal model data, almost none of the early agents identified and tested have made it past clinical trials. A new use for thalidomide, which was originally introduced as a sedative and antiemetic drug, was postulated after its metabolites were found to inhibit angiogenesis in a rabbit cornea micropocket assay.21 Unfortunately, early trials showed only modest clinical effectiveness in prostate cancer patients and no antitumor activity in recurrent or metastatic squamous cell carcinoma of the head and neck.22,23 Trials of a host of other antiangiogenic drugs followed with similar results. TNP-470, an analog of fumagillin, generated only one short-lived partial response in 33 patients with metastatic renal carcinoma,24 and a later study also failed to show clinical benefit for prostate cancer.25 In two phase I clinical trials, angiostatin, which is a naturally occurring angiogenesis inhibitor,26 showed no clinical response with several types of solid tumors.27,28 Likewise, endostatin, another natural angiogenesis inhibitor,29 showed only minor antitumor activity in a phase I trial30 and no significant tumor regression in patients with advanced neuroendocrine tumors in a phase II trial.31 In a phase II clinical trial of ABT-510, which is a peptide mimetic of thrombospondin type 1 (yet another endogenous angiogenesis inhibitor), only 3 out of 21 late-stage malignant melanoma patients showed stable disease, and no definite clinical efficacy was demonstrated.32 Another phase II trial also showed only one objective response out of 88 patients with advanced soft tissue sarcoma.33

The mechanisms of action for all the previously discussed drugs are poorly or only partially understood. Agents with specific molecular targets in the angiogenic signaling pathways were explored as alternatives. This approach, however, also had several disappointments before any measure of clinical success was achieved. SU5416, which is a small synthetic receptor tyrosine kinase inhibitor of the VEGF receptor VEGFR-2, produced no objective response in 27 patients with refractory multiple myeloma. Two other phase II trials showed either no or rare responses in patients with advanced soft tissue sarcomas and recurrent head and neck cancers.34 PTK787/ZK 222584, which is another small molecule tyrosine kinase receptor inhibitor targeting all of the VEGF receptors, also failed to produce significant responses in patients with acute myeloid leukemia.35

Signs of success

In 2003, an anti-VEGF humanized monoclonal antibody, bevacizumab, made its debut with only slightly better results as a monotherapy in metastatic renal cancer patients;36 when compared with a placebo, high-dose bevacizumab had only a 10% response rate with modestly prolonged progression-free survival but no overall survival benefit. Although these initial results were disappointing, evidence of the efficacy of bevacizumab came shortly thereafter, leading to an eventual paradigm shift in the concept of antiangiogenic therapy. In June 2004, Hurwitz et al reported a phase III trial showing substantial improvement in overall survival (about a 5-month increase) in patients with metastatic colorectal cancer when treated with bevacizumab combined with irinotecan,
fluorouracil, and leucovorin. Although a handful of phase III trials involving treatment of different cancers by combining bevacizumab with various regimens have shown improvement only in progression-free survival but not overall survival, most reported studies have shown increased overall survival along with increased progression-free survival when bevacizumab is added to the treatment regimen. These include a 2-month overall survival benefit in patients with metastatic renal cell carcinoma when treated with bevacizumab in combination with interferon α-2a, in patients who had previously been treated for metastatic colorectal cancer when combined with oxaliplatin, fluorouracil, and leucovorin; and in patients with non-small-cell lung cancer when combined with paclitaxel and carboplatin. A 3-month overall survival benefit was also reported in patients with metastatic colorectal cancer treated with bevacizumab in combination with fluorouracil and leucovorin. Therefore, in most cases, an apparent synergy is seen in which bevacizumab has clinical benefit when combined with cytotoxic chemotherapies.

It is also interesting to note that thalidomide, as discussed earlier, has not been proven effective as a monotherapy, but, when combined with melphalan, a cytotoxic alkylating agent, and prednisone, an immunosuppressing corticosteroid, it increases median overall survival by nearly 18 months in elderly patients with multiple myeloma, possibly by reducing bone marrow vascularization. Still, even with these first signs of success involving bevacizumab and thalidomide, tumors did become resistant relatively quickly and overall improvement was modest.

**Normalization of tumor vasculature**

With these clinical data has come a paradox. If antiangiogenic therapy destroys tumor vasculature, a reduction of drug delivery would be expected. Why then does antiangiogenesis enhance tumor killing when combined with cytotoxic agents? Perhaps even more puzzling is the observation that anti-VEGF therapy can increase tumor irradiation efficacy, which is largely dependent on tissue oxygenation.

To account for these apparently conflicting findings, Jain posited that, in addition to destroying vasculature for depriving the tumor of oxygen and nutrients, antiangiogenic agents also transiently ‘normalize’ the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Vasculature maintenance involves a homeostatic interplay between pro- and antiangiogenic signals. In normal tissue these signals are balanced, but during neoplastic growth the proangiogenic signals are overexpressed, thereby stimulating inappropriate vessel growth and leading to characteristically disorganized, inefficient, and leaky tumor vasculature. Jain proposed that using a low dose or ‘judicious’ application of antiangiogenic agents could restore the balance in the angiogenic regulation by pruning immature, nonproductive vessels, decreasing vessel permeability, and reducing abnormal dilation. The expected functional consequence of vasculature normalization is decreased interstitial fluid pressure, relieved hypoxic stress, and improved penetration of drugs in the tumor.

Although vasculature normalization has been shown to improve vascular function in preclinical models through intravital imaging studies, it is not straightforward to ascertain in patients the changes in blood flow and distribution within a tumor during antiangiogenic therapy, making it difficult to verify this process. Many questions, such as why there is only a transient ‘normalization window’ and how to identify it, remain unanswered.

**Negative sequelae of targeting tumor vasculature**

As mentioned earlier, a potential advantage of targeting endothelial rather than tumor cells is the avoidance of drug resistance, because endothelial cells, unlike those of tumors, are genetically stable. However, tumor revascularization following a transient decrease in vessel density with an anti-VEGF receptor agent has been reported, resulting at least in part from increased levels of bFGF.

It has become increasingly clear that VEGF-targeted therapy probably involves multiple mechanisms. A possible explanation for the activation of alternative angiogenic pathways, however, is that antiangiogenesis induces hypoxia, resulting in activation of the hypoxia-inducible factor α (HIF-α), which in turn triggers revascularization of the tumor. HIF-α is known to transcriptionally upregulate a host of pro- and antiangiogenic genes encoding placental growth factor, angiopoietin 1, angiopoietin 2, stromal-derived factor 1, platelet-derived growth factor, and bFGF, as well as VEGF. Given that overexpression of HIF-1α, one of the HIF-α family members (see below), induces nonleaky hypervascularity in transgenic mice, it is conceivable that activated HIF-α could upregulate both pro- and antiangiogenic factors for neovascularization in tumors. Indeed, mice haplodeficient in Egln1, which encodes a negative regulator of HIF-α (see below), showed normalized endothelial lining and vessel maturaion, thereby resulting in improved tumor oxygenation with decreased tumor invasiveness, even though tumor growth was not inhibited.
Irrespective of vasculature regression and/or normalization, a more serious concern with antiangiogenic therapy is that vessel regression may drive tumors toward a more locally invasive and distantly metastatic phenotype. Indeed, increased invasiveness in glioblastoma models was observed after systemic antiangiogenic therapy with an antibody against VEGFR-2, despite a marked inhibition of tumor growth and microvessel density.55,56 Similar results were seen after treatment with bevacizumab in another glioblastoma preclinical study.57 In addition, increased invasiveness after anti-VEGFR-2 treatment was also seen in a pancreatic neuroendocrine cancer mouse model, along with increased liver and lymph node metastases.58 Furthermore, short-term treatment with a potent angiogenic inhibitor, sunitinib/SU11248, also accelerated metastasis into multiple organs in a preclinical study using breast cancer and melanoma cells.59 More troubling is that the invasive nature of the tumors seemed to be permanently established, as removal of treatment did not relieve the aggressive phenotype, possibly suggesting a genetic transformation. Although this increased invasiveness in response to antiangiogenic therapy has not been unequivocally confirmed in patients, partially because of imaging limitations in evaluating these tumors (ie, FLAIR magnetic resonance imaging), it has nonetheless been observed at least subjectively.60 A review of literature indicates that although glioblastoma patients benefit greatly from reduced cerebral edema and intracranial pressure through angiogenic inhibition, tumor invasion continues.61 Additional concerns include that the normalization of tumor vasculature by antiangiogenic agents may restore the blood–brain barrier function, thereby antagonizing the efficacy of chemotherapeutic drugs.

HIF-1α, genetic alteration, and tumor progression

Hypoxia has long been implicated in genetic instability and tumor progression, which may account for the inevitable failure of antiangiogenesis as a monotherapy. Although the mechanisms underlying hypoxia-induced tumor progression remain to be elucidated, recent evidence indicates that HIF-α plays an essential role in tumor growth and progression.

In human cancers, both HIF-1α and HIF-2α, two of the prevalent members of the HIF-α family, are frequently dysregulated, resulting in their overexpression.62 Under physiological conditions when oxygen tension within cells is high, HIF-α is hydroxylated at specific proline residues by the prolyl hydroxylases EGLN1, EGLN2, and EGLN3 (better known as PHD2, PHD1, and PHD3, respectively).63-64 This allows HIF-α to be ubiquitinated by a pVHL-directed E3 ligase and targeted to the proteasome for degradation. In hypoxia, however, the hydroxylation reaction is inhibited; HIF-α accumulates within the cell, translocates to the nucleus, and, upon dimerization with its binding partner aryl hydrocarbon receptor nuclear translocator (ARNT), acts as a transcription factor for the activation of a diverse group of hypoxia-responsive genes.52 This canonical HIF-α–ARNT pathway (Figure 1) has accounted for hypoxic activation of many genes directly related to tumor growth and survival, such as those involved in glycolysis, cell migration, apoptosis, multidrug resistance, extracellular matrix modification, epithelial–mesenchymal transition, and angiogenesis.62,65

Despite these extraordinary insights into the mechanisms underlying tumor biology, how hypoxia drives genetic alteration, the underlying cause of tumor progression, has yet to be elucidated.66,67 Interestingly, we and others began to show recently that HIF-1α and HIF-2α have opposing effects on DNA repair; HIF-1α inhibits, whereas HIF-2α stimulates, DNA repair.59,69 Although how these conflicting effects between HIF-1α and HIF-2α are reconciled within tumor cells needs further investigation, our results demonstrated that HIF-1α, but not HIF-2α, is essential to hypoxic downregulation of the DNA mismatch repair genes MSH2 and MSH670 and the double-strand break repair gene NBN.71 Interestingly, HIF-1α does so by a distinct mechanism that is independent of the HIF-1α–ARNT pathway but involves HIF-1α func-

Figure 1 A schematic representation of the HIF-1α–ARNT pathway and the HIF-1α–c-Myc pathway. Stabilized HIF-1α participates in the canonical HIF-1α–ARNT pathway (–ARNT) through dimerization with its binding partner ARNT, recruitment of the transcription coactivator p300/CBP, and binding to the HRE in the promoter of the angiogenic and glycolytic genes for transcriptional activation. Alternatively, the HIF-1α–c-Myc pathway (–c-Myc) involves HIF-1α competing with c-Myc for binding to the transcription factor Sp1 in the promoter of DNA repair genes, resulting in selective c-Myc displacement and gene repression. Abbreviations: HIF, hypoxia-inducible factor; ARNT, aryl hydrocarbon receptor nuclear translocator; HRE, hypoxia-responsive element.
tionally counteracting c-Myc, a transcriptional activator for maintaining DNA repair gene expression. This HIF-1α–c-Myc pathway accounts not only for hypoxic inhibition of DNA repair but also for resultant DNA damage and genetic alterations (Figure 1). By uncoupling these two distinct, independent pathways of HIF-1α, we have recently shown that the HIF-1α–c-Myc pathway is essential to drive tumor progression, whereas the HIF-1α–ARNT pathway is more involved in tumor growth. Therefore, the dual functions of HIF-1α may account on the one hand for vasculature normalization resulting from regulated expression of both pro- and antiangiogenic genes via the HIF-1α–ARNT pathway, and on the other hand for tumor progression driven by genetic alterations via the HIF-1α–c-Myc pathway.

With this gained knowledge, we propose that in addition to its important role in angiogenesis and glycolysis for tumor growth and survival, HIF-1α is essential to drive genetic alteration for tumor progression, which is a negative aspect of the hypoxic response enabling tumor cells to evolve through increased genetic heterogeneity. This could explain the ease with which many cancers are able to adapt to a wide variety of therapeutics (including antiangiogenics) and develop resistance. It could also explain the apparent genetic changes that lead to increased invasion and metastasis in antiangiogenic-treated tumors.

**Future directions of antiangiogenic therapy**

Although antiangiogenic therapy remains promising, a durable antitumor activity for an improved overall survival is desired. To this end, several hypotheses have been proposed. Pietras and Hanahan suggested the use of broader-spectrum angiogenesis inhibitors or ‘cocktails’ of specific inhibitors as a method of blocking alternative angiogenic pathways that may be activated under a VEGF blockade. They have demonstrated the efficacy of this tactic in an animal model of islet cell carcinogenesis. Treatment with anti-VEGFR-2 antibodies led to an initial decrease in tumor vascularity as well as tumor size. This was followed by revascularization and regrowth of the tumors. Greater response was seen, however, by coinhibiting bFGF, which was suspected in an alternative angiogenic pathway. This resulted in a further decrease in tumor growth after the initial regression.

On the other hand, it stands to reason that if HIF-α can be targeted alongside antiangiogenic agents to prevent the induction of genetic alteration and/or angiogenesis, this could greatly improve the efficacy of antiangiogenic therapy. Interestingly, Melillo and Rapisarda et al have identified a potential HIF-α inhibitor, topotecan. When used alongside bevacizumab in U251 glioma xenografts, topotecan showed considerable synergistic antitumor activity. Not only was tumor volume decreased but intratumor vasculature was also decreased compared with tumors treated with either topotecan or bevacizumab alone. Considering the increased invasive nature of tumors following antiangiogenic treatment, HIF-α targeting may prove to be an effective way of maximizing antiangiogenic therapy in the future. Likewise, drugs that potentially block genetic alteration and thereby tumor progression may greatly improve overall survival when combined with antiangiogenic agents.

**Conclusions**

Antiangiogenic therapy was initially based on the notion that angiogenesis is required for tumor growth, and thus...
destruction of the tumor vasculature would deprive the tumor of oxygen and nutrients, resulting in growth inhibition. However, tumor vasculature is structurally abnormal and functionally inefficient, and the resultant hypoxic microenvironment is associated with tumor progression and resistance to therapies (Figure 2). Therefore, therapeutic destruction of the tumor vasculature is expected to yield more severe hypoxia, which on the one hand induces additional angiogenic responses through the activation of HIF- α for normalizing vasculature, and on the other hand drives genetic alteration for malignant progression. This view accounts for the unexpected clinical outcomes when single antiangiogenesis agents are used, some clinical benefits when antiangiogenesis agents are used in combination with chemotherapies, and fundamentally the inevitable problem of resistance to therapies (Figure 2). Therefore, therapeutic destruction of the tumor vasculature is expected to yield more severe hypoxia, which on the one hand induces additional angiogenic responses through the activation of HIF-α for normalizing vasculature, and on the other hand drives genetic alteration for malignant progression. This view accounts for the unexpected clinical outcomes when single antiangiogenesis agents are used, some clinical benefits when antiangiogenesis agents are used in combination with chemotherapies, and fundamentally the inevitable problem of resistance to therapies (Figure 2).

**Acknowledgments**

We thank Kristin Kraus for editing the manuscript. LEH was supported in part by a Public Health Service grant (CA-131355) from the National Cancer Institute, and CR was supported by a Public Health Service grant (HL-007744) from the National Institute of Diabetes and Digestive and Kidney Diseases.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


